What is the role of pazopanib (Votrient) in the treatment of renal cell carcinoma (RCC)?

Updated: May 21, 2019
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print
Answer

Pazopanib (Votrient) is a oral multi-kinase inhibitor that targets VEGFR, PDGFR, and c-Kit (stem cell receptor factor). The FDA approved pazopanib for the treatment of patients with advanced renal cell carcinoma in 2009.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!